This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: November 6th, 2009 - November 6th, 2010
This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with diffuse large B-cell lymphoma.
This activity was developed for physicians, nurses, and pharmacists.
At the completion of this activity participants should be able to:
- Describe the prevalence, natural history, and clinical features of diffuse large B-cell lymphoma (DLBCL)
- Identify clinical and molecular markers of prognosis in patients with DLBCL
- Review the efficacy and tolerability of current approaches to the management of DLBCL
- Describe novel therapies in development for DLBCL
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakersâ€™ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner
|Amanda Glazar, PhD||Global||Nothing to disclose|
|Jackie Dawson, MSN||Global||Nothing to disclose|
|Nancy Nesser, PharmD, JD||MLI||Nothing to disclose|
|Kathryn Gada, MSN||MLI||Nothing to disclose|
|Dana Delibovi||COEXM||Nothing to disclose|
|Susan Berry||COEXM||Nothing to disclose|
André Goy, MD, MS is on the speaker's bureau and is a consultant for Allos, Biogen Idec, Celgene, Genentech, and Millennium.
Betty M. Chan, PharmD, BCOP has received research/grant support from Merck & Co.
Christine Liebertz, RN, CS, MSN, AOCN has nothing to disclose.
*Content will include non-FDA-approved uses.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.